MorphoSys AG ADR Executives
MorphoSys employs about 464 people. The company is managed by 20 executives with a total tenure of roughly 19 years, averaging almost 0.0 years of service per executive, having 23.2 employees per reported executive. Discussion of MorphoSys' management performance can provide insight into the enterprise performance.
Marlies Sproll Executive Chief Scientific Officer, Member of the Management Board |
MorphoSys |
MorphoSys Management Team Effectiveness
The company has Return on Asset of (0.1384) % which means that on every $100 spent on assets, it lost $0.1384. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.838) %, meaning that it generated no profit with money invested by stockholders. MorphoSys' management efficiency ratios could be used to measure how well MorphoSys manages its routine affairs as well as how well it operates its assets and liabilities.MorphoSys Workforce Comparison
MorphoSys AG ADR is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,320. MorphoSys retains roughly 464 in number of employees claiming about 14% of equities under Health Care industry.
The company has Net Profit Margin of (1.91) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (9.6) %, which entails that for every $100 of revenue, it lost $9.6. MorphoSys Notable Stakeholders
A MorphoSys stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MorphoSys often face trade-offs trying to please all of them. MorphoSys' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MorphoSys' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lucinda Crabtree | CFO Board | Profile | |
Gnter Wellnhofer | Head Operations | Profile | |
Maria Castresana | VP HR | Profile | |
Anja Pomrehn | VP Relations | Profile | |
Lukas Gilgen | Chief Officer | Profile | |
Charlotte Lohmann | Compliance Legal | Profile | |
Sung Lee | CFO Board | Profile | |
Tim MD | Chief Officer | Profile | |
Marlies Sproll | Chief Scientific Officer, Member of the Management Board | Profile | |
Julia Neugebauer | Head Relations | Profile | |
Barbara KrebsPohl | Chief Officer | Profile | |
Arkadius MBA | Chief Officer | Profile | |
Ralf Ostendorp | Head CMC | Profile | |
Harald Watzka | Head Management | Profile | |
Lara Weber | Corp Controlling | Profile | |
JeanPaul MD | MD Board | Profile | |
Margit Urban | Head Technologies | Profile | |
Yen Chua | Head Operations | Profile | |
Klaus Wall | Head Tax | Profile | |
Thomas Biegi | VP Communications | Profile |
About MorphoSys Management Performance
The success or failure of an entity such as MorphoSys AG ADR often depends on how effective the management is. MorphoSys management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MorphoSys management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MorphoSys management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. The company was founded in 1992 and is headquartered in Planegg, Germany. Morphosys operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 648 people.
MorphoSys Workforce Analysis
Traditionally, organizations such as MorphoSys use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MorphoSys within its industry.MorphoSys Manpower Efficiency
Return on MorphoSys Manpower
Revenue Per Employee | 513.5K | |
Revenue Per Executive | 11.9M | |
Net Loss Per Employee | 408.9K | |
Net Loss Per Executive | 9.5M | |
Working Capital Per Employee | 1.2M | |
Working Capital Per Executive | 27.5M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Fundamental Analysis View fundamental data based on most recent published financial statements |